Imaging has the potential to dramatically increase the efficiency of lead candidate selection by providing earlier and more highly predictive data, compared with traditional methods. Imaging is also well suited for facilitating translation between preclinical testing and clinical evaluation of drugs. Furthermore, imaging methods are more easily applied than traditional methods in the newer, more realistic models of human disease that are becoming increasingly prevalent. This video on MRI imaging showcases our expertise and large scale capabilities. Charles River has an in vivo imaging facility with high-field MRI, PET/CT and SPECT/CT scanners for radionuclide-based imaging applications. All platforms are applicable for longitudinal studies with multiple imaging endpoints to study phenotype progression and treatment efficacy, biodistribution or tissue activity changes. Request imaging information » We've answered some frequently asked questions about imaging below. You can also learn more by watching our nuclear imaging webinar. Can imaging be performed along with other tests in the same animal? Yes. The advantage of nuclear imaging is that it can be combined with other studies such as behavioral studies, histology and anatomical image MRIs. When biochemical analyses (e.g., IHC, Western blotting, microscopy) are performed on postmortem samples from animals injected with radioactive tracers, are these analyses conducted in a lab certified for isotope work or are the samples stored in quarantine until the isotope decays? It depends on the half-life of the isotope. It is possible to store samples that have shorter half-life isotopes before performing additional analyses but in cases where the isotope half-life is very long (such as 14C), the sample will need to be analyzed in a lab certified for isotope work. Can the distribution of supramolecular structures (e.g., liposomes, nanoparticles) be imaged? Yes. We have done nanoparticle distribution studies and plan to increase our capabilities in imaging supramolecular structures. Does Charles River offer receptor occupancy studies and how do these studies compare with PET imaging data? We offer receptor occupancy studies using H-3 labeled compounds but we do not have comparison data between H-3 studies and PET imaging at this time. The availability of the ligands has not yet supported this work. For the 18F-TSPO ligand, is autoradiography preferred over PET imaging for the EAE, cuprizone and LPS models? It depends on the data that needs to be generated. If the imaging needs to be done more slowly over a longer time period, then autoradiography is preferable as it has a larger time window. PET imaging is preferable for more sensitive data output. Does Charles River have access to a cyclotron? Can custom radiolabeling of molecules with F-18, radioiodines and radiometals be performed? Charles River has access to a local cyclotron and we have an agreement in place to synthesize custom ligands and perform radiolabeling. Current radiolabeling capabilities include fluoride-18, carbon-11 and gallium-68 PET ligand nuclides. Iodine-125 labeling is also possible. Does Charles River have the ability to measure in vivo bioluminescence using reporter mice? Yes. We can measure bioluminescence at the Charles River Finland site. Please email firstname.lastname@example.org to get more information. What is a typical sample size for efficacy studies using PET/SPECT imaging? Reference efficacy studies can be performed with a group of 5 animals. For a novel compound study using PET imaging, the recommended sample size is at least 10 animals for statistically significant data. Has Charles River used imaging to quantify amyloid plaques in models of Alzheimer’s disease? Yes. We have ongoing studies to quantify amyloid plaques in mouse models of Alzheimer’s disease. Do you have the hardware and skills for multi-spectral optoacoustic tomography for use with fluorescent probes? At this time, we do not have optoacoustic imaging capabilities in house and it is important to note that this imaging modality has major challenges - limited depth of light penetrance in brain tissues and the barrier presented by the skull. However, we do have collaborations in place to perform imaging using fluorescent probes. I need to... Correlate anatomical information with functional information. Analyze brain activity. Determine metabolite concentrations for neurochemical profiling and assess treatment response in vivo.